How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/attention-deficit-hyperactivity-disorder.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Attention deficit hyperactivity disorder — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Attention deficit hyperactivity disorder (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Attention deficit hyperactivity disorder, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Azstarys	SERDEXMETHYLPHENIDATE	Commcave Therapeutics Sa			2021-01-01
Vyvanse	LISDEXAMFETAMINE	Takeda	Central Nervous System Stimulant	Sodium-dependent dopamine transporter	2007-01-01
Strattera	ATOMOXETINE	Eli Lilly	Norepinephrine Reuptake Inhibitor	Sodium-dependent noradrenaline transporter	2002-01-01
Focalin	DEXMETHYLPHENIDATE	Novartis	Central Nervous System Stimulant	Sodium-dependent dopamine transporter	2001-01-01
Tenex	GUANFACINE	Promius Pharma	Central alpha-2 Adrenergic Agonist	Nischarin	1986-01-01
Catapres-Tts-1	CLONIDINE	Lavipharm	Central alpha-2 Adrenergic Agonist	Alpha-2A adrenergic receptor	1974-01-01
Amphetamine Sulfate	AMPHETAMINE SULFATE	Azurity	Central Nervous System Stimulant	Sodium-dependent dopamine transporter	1955-01-01
Xelstrym	dexamfetamine	UCB	Central Nervous System Stimulant [EPC]	Sodium-dependent noradrenaline transporter	1955-01-01
Amphetamine Sulfate	amfetamine	UCB	Central Nervous System Stimulant	Sodium-dependent dopamine transporter	1955-01-01
Desoxyn	METHAMPHETAMINE	Ajenat Pharms	Amphetamine Anorectic	Sodium-dependent noradrenaline transporter	1943-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

UCB · 2 drugs in Attention deficit hyperactivity disorder
Novartis · 2 drugs in Attention deficit hyperactivity disorder
· 2 drugs in Attention deficit hyperactivity disorder
Commcave Therapeutics Sa · 1 drug in Attention deficit hyperactivity disorder
Eli Lilly · 1 drug in Attention deficit hyperactivity disorder
Fudan University · 1 drug in Attention deficit hyperactivity disorder
Lavipharm · 1 drug in Attention deficit hyperactivity disorder
Lei Lei, MD · 1 drug in Attention deficit hyperactivity disorder
Medical University of Vienna · 1 drug in Attention deficit hyperactivity disorder
Promius Pharma · 1 drug in Attention deficit hyperactivity disorder
Takeda · 1 drug in Attention deficit hyperactivity disorder
University of Oklahoma · 1 drug in Attention deficit hyperactivity disorder

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Attention deficit hyperactivity disorder:

Cite this brief

Drug Landscape (2026). Attention deficit hyperactivity disorder — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/attention-deficit-hyperactivity-disorder. Accessed 2026-06-10.

Attention deficit hyperactivity disorder full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing